Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., … Bigner, D. (2006). Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study. In NEURO-ONCOLOGY (Vol. 8, pp. 489–489). Vienna, AUSTRIA: DUKE UNIV PRESS.

Reardon, D., G. Akabani, A. Friedman, H. Friedman, J. Herndon, R. McLendon, J. Quinn, et al. “Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study.” In NEURO-ONCOLOGY, 8:489–489. DUKE UNIV PRESS, 2006.

Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McLendon R, et al. Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2006. p. 489–489.

Reardon, D., et al. “Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study.” NEURO-ONCOLOGY, vol. 8, no. 4, DUKE UNIV PRESS, 2006, pp. 489–489.

Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, Vredenburga J, Dejardins A, Sampson J, Gururangan S, Kirkpatrick J, Wong T, Dowell J, Dunn R, Sathornsumettee S, Boutlton S, Coleman R, Zalutsky M, Bigner D. Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2006. p. 489–489.